15,864 results on '"B cell lymphoma"'
Search Results
2. Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
- Author
-
Genentech, Inc.
- Published
- 2024
3. Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
- Published
- 2024
4. CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
- Published
- 2024
5. A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
- Author
-
Genentech, Inc. and Kite, A Gilead Company
- Published
- 2024
6. Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
- Author
-
Pfizer
- Published
- 2024
7. Long-Term Follow-up Study (LTFS)
- Published
- 2024
8. BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)
- Published
- 2024
9. CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
- Published
- 2024
10. CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL (CRETI-NH)
- Author
-
The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine, and Carlos Ramos, Assistant Professor
- Published
- 2024
11. Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
- Author
-
Merck Sharp & Dohme LLC
- Published
- 2024
12. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Published
- 2024
13. Primary Breast Lymphoma: A Case Report of a Common Tumor in an Uncommon Location.
- Author
-
Mremi, Alex, Chipongo, Hilary, Urassa, Ellyagape, Mkwizu, Elifuraha, and Lodhia, Jay
- Subjects
- *
BREAST cancer prognosis , *THERAPEUTIC use of antineoplastic agents , *BREAST tumor diagnosis , *BREAST tumor treatment , *BREAST exams , *BIOPSY , *RADIOTHERAPY , *LACTATE dehydrogenase , *CYTOCHEMISTRY , *RITUXIMAB , *IMMUNOHISTOCHEMISTRY , *CANCER chemotherapy , *TUMOR antigens , *B cell lymphoma , *BREAST , *LYMPHATIC diseases - Abstract
Primary breast lymphoma (PBL) is a rare malignant lymphoid neoplasm limited to the breast, accounting for about 0.15% of all malignant breast tumors and 1.7% to 2.2% of extra-nodal lymphomas. PBL must be distinguished from conventional breast carcinomas due to different therapeutic approaches. A 25-year-old female presented with a left breast mass. Histopathology and immunohistochemical tests confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). She had no similar lesions elsewhere in the body. She received 1 cycle of R-CHOP chemotherapy but absconded from the treatment and succumbed afterward while at home. Recent developments in DLBCL treatment have greatly improved patient outcomes by incorporating targeted medicines like rituximab, increased chemotherapy regimens, new drugs, and individualized treatment techniques. PBL appears to have a worse prognosis; thus, delay or abscondment from treatment is of serious concern when it comes to improving the prognosis of patients with PBL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Primary neurolymphomatosis with MAG antibody: a case report.
- Author
-
Zhang, Honglian, Chen, Si, Li, Jing, Yang, Huan, and Luo, Yue-Bei
- Subjects
- *
B cell lymphoma , *CAUDA equina , *CEREBROSPINAL fluid , *HYDROCEPHALUS , *CRANIAL nerves - Abstract
Neurolymphomatosis (NL) is a rare neurologic manifestation of non-Hodgkin lymphoma (NHL) with poor prognosis. Investigations including MRI, PET/CT, nerve biopsy and cerebrospinal fluid (CSF) analysis can aid the diagnosis of NL. In this study, we presented a case of NL with co-existing myelin-associated glycoprotein (MAG) antibody. The patient first presented with symptoms of peripheral neuropathy involving multiple cranial nerves and cauda equina, and later developed obstructive hydrocephalus and deep matter lesions. He also had persistently positive MAG antibody, but did not develop electrophysiologically proven neuropathy and monoclonal immunoglobulin. The final brain biopsy confirmed diffuse large B cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. USP19 exerts a tumor‐promoting role in diffuse large B cell lymphoma through stabilizing PARK7.
- Author
-
Li, Yaqing, Liu, Xiyang, Li, Yulai, Wang, Jieting, Zhang, Mengqian, Xue, Weili, and Zhang, Mingzhi
- Subjects
- *
B cell lymphoma , *GENE expression profiling , *DIFFUSE large B-cell lymphomas , *GENE expression , *PARKINSON'S disease , *PEPTIDASE - Abstract
Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma and is associated with a poor prognosis. Data from the Gene Expression Profiling Interactive Analysis (GEPIA) database revealed dysregulated expression of several ubiquitin‐specific proteases (USPs) in DLBCL tissues (DLBCL vs. non‐DLBCL = 47 vs. 337), including USP19 (log2fold change = 1.17, P < 0.05). USP19 is closely linked to tumorigenesis, but its role in DLBCL progression remains largely unknown. Here, we investigated the role of USP19 in DLBCL development. Genetic manipulation of USP19 using adenovirus‐based vectors was performed in two DLBCL cell lines, SUDHL4 and DB cells. The results showed that USP19 knockdown suppressed the proliferation, anchorage‐independent growth and xenograft tumor formation of DLBCL cells and arrested the cell cycle at the G1 stage. In parallel, DLBCL cells overexpressing USP19 acquired a more malignant phenotype. Next, to explore USP19 interactors, we performed co‐immunoprecipitation/liquid chromatography–mass spectrometry and identified potential interacting proteins. Among them, Parkinson disease protein 7 (PARK7), a member of the peptidase C56 family known to be involved in carcinogenesis, was further validated to bind with and be stabilized by USP19. Additionally, we found that USP19 induced PARK7 deubiquitylation in both DLBCL cell lines, and PARK7 acted as a downstream effector of USP19 in regulating the growth of DLBCL cells. Collectively, USP19 exerts a tumor‐promoting role in DLBCL through interacting with and stabilizing PARK7. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Investigating the frequency of somatic MYD88 L265P mutation in primary ocular adnexal B cell lymphoma.
- Author
-
Saraswathi, Karuvel Kannan, Santhi, Radhakrishnan, Kim, Usha, and Vanniarajan, Ayyasamy
- Abstract
Background: Ocular adnexal B cell lymphoma is the most common orbital malignancy in adults. Large chromosomal translocations and alterations in cell-signaling pathways were frequently reported in lymphomas. Among the altered pathways, perturbations of NFκB signaling play a significant role in lymphomagenesis. Specifically, the MYD88 L265P mutation, an activator of NFκB signaling, is extensively studied in intraocular lymphoma but not at other sites. Therefore, this study aims to screen the MYD88 L265P mutation in Ocular adnexal B cell lymphoma tumors and assess its clinical significance. Methods and results: Our study of twenty Ocular adnexal B cell lymphoma tumor samples by Allele-Specific Polymerase Chain Reaction identified two samples positive for the MYD88 L265P mutation. Subsequent Sanger sequencing confirmed the presence of the heterozygous mutation in those two samples tested positive in Allele-Specific Polymerase Chain Reaction. A comprehensive review of MYD88 L265P mutation in Ocular adnexal B cell lymphoma revealed variable frequencies, ranging from 0 to 36%. The clinical, pathological, and prognostic features showed no differences between patients with and without the MYD88 L265P mutation. Conclusion: The present study indicates that the MYD88 L265P mutation is relatively infrequent in our cohort, underscoring the need for further validation in additional cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma.
- Author
-
Li, Jian-Rong, Shaw, Vikram, Lin, Yupei, Wang, Xiang, Aminu, Muhammad, Li, Yong, Wu, Jia, Zhang, Jianjun, Amos, Christopher I., and Cheng, Chao
- Subjects
- *
B cell lymphoma , *CYTOTOXIC T cells , *B cells , *CELL morphology , *CANCER cells - Abstract
The spatial arrangement of immune cells within the tumor microenvironment (TME) and their interactions play critical roles in the initiation and development of cancer. Several advanced technologies such as imaging mass cytometry (IMC) providing the immunological landscape of the TME with single-cell resolution. In this study, we develop a new method to quantify the spatial proximity between different cell types based on single-cell spatial data. Using this method on IMC data from 416 lung adenocarcinoma patients, we show that the proximity between different cell types is more correlated with patient prognosis compared to the traditional features such immune cell density and fractions. Consistent with previous reports, our results validate that proximity of T helper (Th) and B cells to cancer cells is associated with survival benefits. More importantly, we discover that the proximity of M2 macrophages to multiple immune cells is associated with poor prognosis. When Th/B cells are stratified into M2-distal and M2-proximal, the abundance of the former but not the latter category of Th/B cells is correlated with enhanced patient survival. Additionally, the abundance of M2-distal and M2-proximal cytotoxic T cells (Tc) is respectively associated with good and poor prognosis. Our results indicate that the prognostic effect of Th, Tc, and B cells in the tumor microenvironment is modulated by the nearby M2 macrophages. The proposed new method proposed can be readily applied to all single-cell spatial data for revealing functional impact of immune cell interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Evaluation of analytical performance of AQUIOS CL flow cytometer and method comparison with bead-based flow cytometry methods.
- Author
-
Chiron, Andrada S., Locher, Lucy, Sarthou, Aurélie, Gleizes, Aude, Krzysiek, Roman, Chretien, Pascale, and Hacein-Bey-Abina, Salima
- Subjects
- *
LYMPHOCYTE subsets , *B cell lymphoma , *FLOW cytometry , *COMPARATIVE literature , *INTERNATIONAL organization - Abstract
Given that method validation is mandatory for compliance with the International Organization for Standardization (ISO) 15,189 standard requirements, we evaluated the analytical performance of the AQUIOS CL system (Beckman Coulter) and compared it with two bead-based flow cytometry (FCM) protocols (BD FACSCAntoTM-II and Beckman Coulter DxFLEX). There are no comparative literature data on standardized protocols for counting lymphocyte subsets on the new-generation cytometer DxFLEX. We evaluated the AQUIOS CL's performance with regard to accuracy, linearity and stability by using dedicated control cell samples and patient samples. We also compared the lymphocyte counts measured on the AQUIOS CL (n=69 samples) with those measured on the BD FACSCAntoTM-II and DxFLEX FCM systems. For 61 samples, FCM results were compared with those measured on the XN-3000 Sysmex hematology analyzer. AQUIOS CL showed acceptable performance – even outside the manufacturer's quantification ranges- and strong correlations with bead-based FCM methods. The FCM techniques and the XN-3000 gave similar absolute lymphocyte counts, although values in samples with intense lymphocytosis (B cell lymphoma/leukemia) were underestimated. The AQUIOS CL flow cytometer is a time-saving, single-platform system with good performance, especially when the manufacturer's instructions for use are followed. However, AQUIOS CL's possible limitations and pitfalls impose validation of a bead-based FCM method for immunophenotyping verification or as a back-up system. Although the DxFLEX flow cytometer is more time-consuming to use, it can provide standardized lymphocyte subset counts in case of aberrant results on AQUIOS CL or in the event of equipment failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements.
- Author
-
Gagnon, Marie-France, Meyer, Reid G, Weaver, Eric J, Wood, Adam J, Dupuy, Dudley A, Menachery, Sudeep J, Shi, Min, Baughn, Linda B, Ketterling, Rhett P, and Peterson, Jess F
- Subjects
- *
PROTEIN metabolism , *FLOW cytometry , *GENE rearrangement , *RARE diseases , *GENE expression , *ONCOGENES , *FLUORESCENCE in situ hybridization , *B cell lymphoma , *GENETIC profile , *PHENOTYPES - Abstract
Several reports of concurrent MYC , BCL2 , BCL6 , and CCND1 rearrangements in high-grade B-cell lymphoma (HGBL) have been recently described. Herein, we aimed to delineate the scope of this entity through a review of HGBL with a "quadruple-hit" genetic profile identified at our institution. We performed a retrospective review (2015-2023) at our institution of B-cell lymphoma (BCL) cases that were evaluated with concurrent MYC , BCL2 , and BCL6 break-apart and IGH::MYC and IGH::CCND1 dual-color dual-fusion fluorescence in situ hybridization studies. Of 203 cases meeting inclusion criteria, 2 (1%) with a quadruple-hit genetic profile were identified. Case 1 represented a 59-year-old female with widespread lymphadenopathy and a diagnosis of HGBL who exhibited primary refractoriness to dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) chemotherapy. Case 2 represented a 58-year-old male with mediastinal and abdominal lymphadenopathy and a diagnosis of large BCL who died from disease after 1 cycle of DA-EPOCH-R chemotherapy. Similarly, a literature review of 7 previously reported cases of HGBL with a quadruple-hit profile also demonstrated aggressive disease behavior. Our study adds 2 new cases to the rarely encountered quadruple-hit HGBL, and a brief meta-analysis of the 9 available cases indicates aggressive disease behavior conferred by this constellation of genetic events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Population pharmacokinetics of free and liposome-encapsulated mitoxantrone in patients with relapsed/refractory lymphoma or small cell lung cancer.
- Author
-
Xu, Gaoqi, Yang, Dihong, Ding, Haiying, Zhong, Like, Zhu, Junfeng, Mi, Xiufang, Zhang, Xueyuan, Wu, Zhufeng, Xin, Wenxiu, Li, Chunlei, Wang, Jiaqi, and Fang, Luo
- Subjects
- *
MITOXANTRONE , *DESCRIPTIVE statistics , *LUNG tumors , *COMPARATIVE studies , *B cell lymphoma - Abstract
Objective: This study is aimed at investigating the pharmacokinetic (PK) characteristics of pegylated liposomal mitoxantrone (PLM) in patients with relapsed/refractory lymphoma or small cell lung cancer (SCLC) by constructing population pharmacokinetic (popPK) models for both liposome-encapsulated mitoxantrone and free mitoxantrone. Methods: A total of 23 patients with relapsed/refractory lymphoma and 42 patients with SCLC were included. A popPK model was simultaneously developed utilizing a non-linear mixed effects model (NONMEM) to explore the PK profiles of liposome-encapsulated mitoxantrone and free mitoxantrone. Clearance (CL) and distribution volume (V) were calculated, and covariate analysis was employed to evaluate the influence of patient disease type, demographic information, and biochemical indicators of liver and kidney function on PK parameters. Results: The concentration-time profiles for both liposome-encapsulated mitoxantrone and free mitoxantrone were described by a one-compartment model. The release (Rel) of liposome-encapsulated mitoxantrone to free mitoxantrone was determined to be 0.0191 L/h, and the V of liposome-encapsulated mitoxantrone was 2.32 L. The apparent CL of free mitoxantrone was estimated at 1.66 L/h. The apparent V of free mitoxantrone was 35.8 L in patients with relapsed/refractory lymphoma and 22.2 L for patients with SCLC. In patients with relapsed/refractory lymphoma, lower maximum concentration (Cmax) and higher apparent V of free mitoxantrone were observed compared with patients with SCLC. Conclusion: The popPK characteristics of both liposome-encapsulated and free mitoxantrone in patients with relapsed/refractory lymphoma or SCLC were effectively described by a one-compartment model. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
- Author
-
Schett, Georg, Müller, Fabian, Taubmann, Jule, Mackensen, Andreas, Wang, Wei, Furie, Rich A., Gold, Ralf, Haghikia, Aiden, Merkel, Peter A., Caricchio, Roberto, D'Agostino, Maria-Antonietta, Locatelli, Franco, June, Carl H., and Mougiakakos, Dimitrios
- Subjects
- *
CHIMERIC antigen receptors , *B cell lymphoma , *SYSTEMIC lupus erythematosus , *CD19 antigen , *B cells , *AUTOIMMUNE diseases , *NEUROMYELITIS optica - Abstract
Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T cells with the capacity to deplete B cells and/or plasma cells has tremendous therapeutic potential in autoimmune diseases. In the past few years, CD19-based and B cell maturation antigen (BCMA)-based CAR T cell therapies have been applied to various B cell-mediated autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis and multiple sclerosis. The scientific rationale behind this approach is that deep depletion of B cells, including autoreactive B cell clones, could restore normal immune function, referred to as an immune reset. In this Review, we discuss important aspects of CAR T cell therapy in autoimmune disease, including considerations relating to patient selection, safety, efficacy and medical management. These considerations are based on the early experiences of CAR T cell therapy in autoimmune diseases, and as the field of CAR T cell therapy in autoimmune diseases continues to rapidly evolve, these issues will remain subject to ongoing refinement and adaptation. CAR T cell therapy shows promise for achieving long-term drug-free remission in various autoimmune diseases. This Review discusses the ongoing challenges and unanswered questions of CAR T cell therapy in autoimmune diseases, including pre-procedural, procedural and post-procedural considerations. Key points: Chimeric antigen receptor (CAR)-expressing cells provide a new and powerful treatment strategy for severe forms of various autoimmune diseases. The CAR-expressing cells applied so far have typically been T cells that recognize B cell-specific or plasma cell-specific antigens such as CD19 or BCMA (B cell maturation antigen), respectively. Currently, most information on the treatment of autoimmune disease with CAR-expressing cells comes from the treatment of patients with autologous CD19-targeting CAR T cells. The success of treating autoimmune disease with CAR-expressing cells is dependent on various pre-procedural, procedural and post-procedural factors; these factors are important considerations that warrant further investigation in future studies. Critical patient selection and careful monitoring for both efficacy and toxicity are paramount for successful treatment with CAR-expressing cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
- Author
-
Holtermann, Anne, Gislon, Mila, Angele, Martin, Subklewe, Marion, von Bergwelt-Baildon, Michael, Lauber, Kirsten, and Kobold, Sebastian
- Subjects
- *
CHIMERIC antigen receptors , *B cell lymphoma , *CELLULAR therapy , *TUMOR microenvironment , *IMMUNE response - Abstract
Chimeric antigen receptor T cell therapy has been established in the treatment of various B cell malignancies. However, translating this therapeutic effect to treat solid tumors has been challenging because of their inter-tumoral as well as intratumoral heterogeneity and immunosuppressive microenvironment. Local interventions, such as surgery, radiotherapy, local ablation, and locoregional drug delivery, can enhance chimeric antigen receptor T cell therapy in solid tumors by improving tumor infiltration and reducing systemic toxicities. Additionally, ablation and radiotherapy have proven to (re-)activate systemic immune responses via abscopal effects and reprogram the tumor microenvironment on a physical, cellular, and chemical level. This review highlights the potential synergy of the combined approaches to overcome barriers of chimeric antigen receptor T cell therapy and summarizes recent studies that may pave the way for new treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients.
- Author
-
Cheng, Shijia, Yan, Zheng, Ma, Hongxia, and Liu, Yanyan
- Subjects
- *
HEMOPHAGOCYTIC lymphohistiocytosis , *KILLER cells , *B cell lymphoma , *OVERALL survival , *SURVIVAL rate - Abstract
To explore the clinical features, treatment, and prognosis of patients with lymphoma-associated hemophagocytic syndrome (LAHS) in a real-world clinical setting. We retrospectively examined LAHS patients diagnosed at our center between January 2016 and August 2023, focusing primarily on their clinical features, therapeutic approaches, overall response rate (ORR), and overall survival (OS). A combination of univariate and multivariate analyses was conducted to identify potential prognostic factors. A total of 86 patients diagnosed with LAHS were included to evaluate clinical characteristics and prognostic factors. Patients with T/NK cell lymphoma had a higher probability of developing hemophagocytic syndrome (HPS) during the clinical process than those with B cell lymphoma. The median survival time was 55 days for all patients, and 47 and 81 days for the T/NK cell LAHS and B cell LAHS cohorts, respectively (P = 0.025). Among the patients evaluated, the ORR was 42.2%. Patients starting with anti-lymphoma treatment had a better, albeit not significant, ORR than those beginning with anti-HPS treatment. In the univariate analysis, T/NK cell LAHS (P = 0.027), HPS onset at relapse (P = 0.036), higher baseline plasma EBV-DNA levels (> 4,000 copies/mL, P = 0.034), and treatments including cytokine adsorption and ruxolitinib (P < 0.001 and P = 0.017, respectively) were potentially associated with worse OS, while corticosteroid therapy benefited OS. In the multivariate analysis, T/NK cell LAHS (adjusted hazard ratio (aHR) = 2.007), cytokine adsorption therapy (aHR = 4.547), and corticosteroid therapy (aHR = 0.118) were independently associated with mortality. T/NK cell lymphoma was the main cause of LAHS and carried a worse prognosis. Whether anti-lymphoma or anti-HPS treatment should start first still requires prospective studies with larger sample sizes. The key point in controlling HPS is to block the cytokine storm promptly. Corticosteroid therapy is both effective and accessible and should be used early and in sufficient quantities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Synergistic effect of chimeric antigen receptor modified with Bcl-2 on enhanced solid tumour targeting.
- Author
-
Wang, Xiaoyan, Liu, Guodong, Huan, Tian, Wang, Yuxing, Jiang, Bo, Liu, Wei, Dai, Anran, Zhang, Xiangzhi, and Yu, Feng
- Subjects
EPIDERMAL growth factor receptors ,B cell lymphoma ,TREATMENT effectiveness ,CHIMERIC antigen receptors ,T cells - Abstract
Engineered T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic effects on haematological malignancies. However, CART cells are less effective on solid tumours mainly due to their weak persistence, which might be caused by activation-induced cell death (AICD). To overcome this limitation, CART cell with the antigen, Epidermal growth factor receptor variant III (EGFRvIII), targeting was modified to carry the anti-apoptotic molecule B cell lymphoma 2 (Bcl-2), and the final construct was named as EGFRvIII·CART-Bcl2 cells. Compared with the EGFRvIII·CART cells, EGFRvIII·CART-Bcl2 cells revealed higher capacities of proliferation, anti-apoptosis and tumour cell killing in vitro. Moreover, EGFRvIII·CART-Bcl2 cells had a longer persistence rate and exerted better anti-tumour effects than EGFRvIII·CART cells in cervical carcinoma xenograft model. Taken together, our findings suggest that incorporating anti-apoptotic molecules into CART cells may enhance its therapeutic effects against solid tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
- Author
-
Delamain, Marcia Torresan, Cardoso, Ana Carolina Ferreira, Pericole, Fernando Vieira, da Silva Araújo, Sérgio Shusterschitz, Fogliatto, Laura, Higashi, Marcia, Pereira, Juliana, da Silva, Roberto Luiz, Werutsky, Gustavo, de Paulo Giacon Radtke, Patrícia, Salvino, Marco Aurélio, and Castilho, Vivienne
- Subjects
THERAPEUTIC use of antineoplastic agents ,PATIENT safety ,RESEARCH funding ,SURVIVAL rate ,SCIENTIFIC observation ,RITUXIMAB ,RETROSPECTIVE studies ,DESCRIPTIVE statistics ,PREDNISONE ,KAPLAN-Meier estimator ,VINCRISTINE ,DRUG efficacy ,MEDICAL records ,ACQUISITION of data ,DOXORUBICIN ,BIOSIMILARS ,DATA analysis software ,CONFIDENCE intervals ,PROGRESSION-free survival ,B cell lymphoma ,CYCLOPHOSPHAMIDE ,OVERALL survival ,DISEASE progression ,EVALUATION - Abstract
Introduction: RTXM83, a biosimilar of rituximab, was approved after physicochemical, functional, non-clinical, and clinical studies demonstrated their similarity; these studies included RTXM83-AC-01-11, a multicentric double-blind international prospective pivotal study. Long-term data on biosimilars can potentially elucidate their clinical robustness and facilitate their broader adoption. Methods: In this retrospective observational study, we analyzed a dataset from a Brazilian cohort previously randomized in the RTXM83-AC-01-11 study followed by the assessment of long-term outcomes in an observational extension phase from randomization in the RTXM83-AC-01–11 study to the last recorded evaluation. Patients with diffuse large B cell lymphoma (DLBCL) received either reference rituximab (R) or RTXM83 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as adjuvant treatment. Results: The median follow-up period was 77.0 months. Patients with initial DLBCL stages III and IV comprised 50% of the R-CHOP group and 40% of the biosimilar group. Five (18.5%) patients, including two RTXM83-CHOP-treated and three R-CHOP-treated individuals, experienced late adverse events (AEs) of interest. No new safety signs were established. At the final assessment, the progression-free survival (PFS) rates were 93.3% and 50.0% in the RTXM83-CHOP and R-CHOP groups, respectively. Median PFS was not achieved in the RTXM83-CHOP group, which was 40.5 months in the R-CHOP group. The overall survival (OS) rates were 100% and 66.7% in the RTXM83-CHOP and R-CHOP groups, respectively. The median OS was not reached in any group. Conclusion: This study demonstrated the long-term safety and effectiveness of RTXM83 in treating DLBCL; outcomes comparable to those of the reference product and potentially improved access to treatment have been indicated. However, further research with more diverse patient groups can validate these findings and advocate the broader adoption of biosimilars in cancer care. Trial Registration: ClinicalTrials.gov Identifier: NCT04928573. June 16, 2021, "retrospectively registered". [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis.
- Author
-
Cai, Xing, Yang, Jinru, Guo, Yusheng, Yu, Yanchao, Zheng, Chuansheng, and Dai, Xiaofang
- Subjects
- *
B cell differentiation , *PLASMA cells , *B cell lymphoma , *B cells , *PROGNOSIS - Abstract
Background: At present, immunotherapy has become a powerful treatment for advanced gastric cancer (AGC), but not all patients can benefit from it. According to the latest research, the impact of B cell subpopulations on the immune microenvironment of gastric cancer (GC) is unknown. Exploring whether the interaction between B cells and tumor cells in GC affects the effectiveness of immunotherapy has attracted our interest. Methods: This study involved the re-analysis of single-cell RNA (scRNA) and spatial transcriptomics (ST) data from publicly available datasets. The focus was on investigating the subpopulations and differentiation trajectories of B cells in the gastric cancer (GC) tumor immune microenvironment (TIME). Spatial transcriptomics (ST) and multiple immunofluorescence (mIF) revealed a clear co-localization pattern between B cells and tumor cells. Multiple immunotherapy datasets were collected to identify unique immunotherapy biomarkers. The unique immunotherapeutic potential of targeting CCL28 was validated through a mouse gastric cancer model. In addition, flow cytometry revealed changes in the tumor immune microenvironment targeting CCL28. Results: The re-analysis of ST data from multiple cancer types revealed a co-localization pattern between B cells and tumor cells. A significant number of IgA plasma cells were identified in the GC TIME. Five different tumor-infiltrating B cell subpopulations and two unique B cell differentiation trajectories were characterized, along with seven GC-related states. By analyzing the communication between GC cells and B cells, it was further discovered that tumor cells can influence and recruit plasma cells through CCL28-CCR10 signaling. Additionally, there was a crosstalk between GC cells and B cells. Finally, we identified the LAMA/CD44 signaling axis as a potential prognostic marker for immunotherapy through a large amount of immunotherapy data. We also validated through various animal tumor models that targeting CCL28 can significantly promote CD8+T cell infiltration and function in the TME by regulating B cell and plasma cell functions, and has the ability to synergize immunotherapy. Conclusion: The co-localization and crosstalk between GC cells and B cells significantly affect the efficacy of immunotherapy, and inhibiting the CCL28-CCR10 signal axis is a potential immunotherapy target for GC. Meanwhile, LAMA/CD44 pair may be a potential adverse indicator for immunotherapy and tumor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.
- Author
-
Pignot, Paul Emile, Bahri, Haifa, Malartre, Stéphanie, Morisset, Stéphane, Lebras, Laure, Guillermin, Yann, Nicolas, Emmanuelle, Rey, Philippe, Belhabri, Amine, Jauffret, Lucie, Fyot, Elodie, Thisse, Audrey, Bocquet, Alexiane, and Michallet, Anne‐Sophie
- Subjects
- *
HODGKIN'S disease , *IMMUNOGLOBULIN heavy chains , *FOLLICULAR lymphoma , *B cell lymphoma , *POSITRON emission tomography - Abstract
This document is a letter to the editor discussing the findings of a study on the use of 18F-FDG PET scans to evaluate patients with follicular lymphoma (FL) and guide their treatment. The study found that patients with a higher total lesion glycolysis (TLG) had a significantly higher relapse rate compared to those with a lower TLG. The authors suggest that FL patients should be evaluated with PET scans at diagnosis and stratified based on TLG and tumor metabolic tumor volume (TMTV) thresholds to determine the appropriate treatment approach. However, it is important to note that this study was retrospective and did not consider comorbidities. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
28. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient's age, and tumor types.
- Author
-
Montagna, Erik, de Campos, Najla Santos Pacheco, Porto, Victoria Alves, da Silva, Giselle Correia Próspero, and Suarez, Eloah Rabello
- Subjects
- *
B cell lymphoma , *MANUFACTURING cells , *T cells , *CHIMERIC antigen receptors , *TRANSMEMBRANE domains - Abstract
CD19-targeted chimeric antigen receptors (CAR) T cells are one of the most remarkable cellular therapies for managing B cell malignancies. However, long-term disease-free survival is still a challenge to overcome. Here, we evaluated the influence of different hinge, transmembrane (TM), and costimulatory CAR domains, as well as manufacturing conditions, cellular product type, doses, patient's age, and tumor types on the clinical outcomes of patients with B cell cancers treated with CD19 CAR T cells. The primary outcome was defined as the best complete response (BCR), and the secondary outcomes were the best objective response (BOR) and 12-month overall survival (OS). The covariates considered were the type of hinge, TM, and costimulatory domains in the CAR, CAR T cell manufacturing conditions, cell population transduced with the CAR, the number of CAR T cell infusions, amount of CAR T cells injected/Kg, CD19 CAR type (name), tumor type, and age. Fifty-six studies (3493 patients) were included in the systematic review and 46 (3421 patients) in the meta-analysis. The overall BCR rate was 56%, with 60% OS and 75% BOR. Younger patients displayed remarkably higher BCR prevalence without differences in OS. The presence of CD28 in the CAR's hinge, TM, and costimulatory domains improved all outcomes evaluated. Doses from one to 4.9 million cells/kg resulted in better clinical outcomes. Our data also suggest that regardless of whether patients have had high objective responses, they might have survival benefits from CD19 CAR T therapy. This meta-analysis is a critical hypothesis-generating instrument, capturing effects in the CD19 CAR T cells literature lacking randomized clinical trials and large observational studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Dysuria and Vaginal Pain, Unusual Manifestations of B-acute Lymphoblastic Lymphoma.
- Author
-
Mitra, Ananya Datta, Mitra, Anupam, Chung, Jong H, and Betts, Elham Vali
- Subjects
- *
SPINAL surgery , *SPINE radiography , *BIOPSY , *VAGINA , *LEG , *RARE diseases , *MAGNETIC resonance imaging , *HIP joint , *DYSURIA , *PAIN , *B cell lymphoma , *BACKACHE - Abstract
Urinary symptoms are one of the most common reasons for emergency visits in females of pediatric age group and can be associated with various conditions like infections (most common), sexual trauma and rarely neoplastic processes. Here, we report a case of a 7-year-old female who presented in the emergency multiple times with the complaints of urinary symptoms and vaginal pain and was empirically treated with antibiotics and antifungals without symptomatic improvement. Her blood tests, physical examination during this time remained unrevealing. She was then transferred to our institution on her third emergency visit for further evaluation. On imaging studies, she was noted to have expansile lesions on her vertebral body at the L4 and T6 levels with compressive myelopathy with multiple bone and soft tissue lesions throughout her lower extremities. Patient developed saddle anesthesia requiring emergent decompression and biopsy of the epidural mass with the final pathology coming back as B-lymphoblastic leukemia/lymphoma. B-ALL/B-LBL is the most common pediatric hematologic malignancy and usually presents with fever, hepatosplenomegaly, lymphadenopathy, bone pain and bleeding. Occasionally, atypical presentations like bone and joint pain, osteoporosis, palpable paravertebral mass have been described. However, this is the first case report to describe a very unusual and unfamiliar presentation of this disease causing significant diagnostic difficulty resulting in delayed treatment. This case report can aid as a reminder that unusual pain or any nonspecific manifestations in pediatric patients, refractory to common treatment should be investigated with extreme diligence not to miss this neoplastic process. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms.
- Author
-
Du, Kai-Xin, Wu, Yi-Fan, Hua, Wei, Duan, Zi-Wen, Gao, Rui, Liang, Jun-Heng, Li, Yue, Yin, Hua, Wu, Jia-Zhu, Shen, Hao-Rui, Wang, Li, Shao, Yang, Li, Jian-Yong, Liang, Jin-Hua, and Xu, Wei
- Subjects
- *
B cell lymphoma , *DIFFUSE large B-cell lymphomas , *MISSENSE mutation , *P53 protein , *SURVIVAL rate - Abstract
TP53 mutation (TP53-mut) correlates with inferior survival in many cancers, whereas its prognostic role in diffuse large B-cell lymphoma (DLBCL) is still in controversy. Therefore, more precise risk stratification needs to be further explored for TP53-mut DLBCL patients. A set of 2637 DLBCL cases from multiple cohorts, was enrolled in our analysis. Among the 2637 DLBCL patients, 14.0% patients (370/2637) had TP53-mut. Since missense mutations account for the vast majority of TP53-mut DLBCL patients, and most non-missense mutations affect the function of the P53 protein, leading to worse survival rates, we distinguished patients with missense mutations. A TP53 missense mutation risk model was constructed based on a 150-combination machine learning computational framework, demonstrating excellent performance in predicting prognosis. Further analysis revealed that patients with high-risk missense mutations are significantly associated with early progression and exhibit dysregulation of multiple immune and metabolic pathways at the transcriptional level. Additionally, the high-risk group showed an absolutely suppressed immune microenvironment. To stratify the entire cohort of TP53-mut DLBCL, we combined clinical characteristics and ultimately constructed the TP53 Prognostic Index (TP53PI) model. In summary, we identified the truly high-risk TP53-mut DLBCL patients and explained this difference at the mutation and transcriptional levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. NK Cell Degranulation Triggered by Rituximab Identifies Potential Markers of Subpopulations with Enhanced Cytotoxicity toward Malignant B Cells.
- Author
-
Wlodarczyk, Marta, Torun, Anna, Zerrouqi, Abdessamad, and Pyrzynska, Beata
- Subjects
- *
ANTIBODY-dependent cell cytotoxicity , *KILLER cells , *B cell lymphoma , *C-kit protein , *TUMOR antigens - Abstract
A promising strategy in cancer immunotherapy is to restore or enhance the cytotoxicity of NK cells, among others, by activating the mechanism of antibody-dependent cellular cytotoxicity (ADCC). Monoclonal antibodies targeting tumor antigens, such as rituximab (targeting CD20), induce NK cell-mediated ADCC and have been used to treat B cell malignancies, such as non-Hodgkin lymphoma, but not always successfully. The aim of this study was to analyze the gene expression profile of the NK cells involved in the cytolytic response stimulated by rituximab. NK cells were co-cultured with rituximab-opsonized Raji cells. Sorting into responder and non-responder groups was based on the presence of CD107a, which is a degranulation marker. RNA-seq results showed that the KIT and TNFSF4 genes were strongly down-regulated in the degranulating population of NK cells (responders); this was further confirmed by qRT-PCR. Both genes encode surface proteins with cellular signaling abilities, namely c-KIT and the OX40 ligand. Consistent with our findings, c-KIT was previously reported to correlate inversely with cytokine production by activated NK cells. The significance of these findings for cancer immunotherapy seems essential, as the pharmacological inhibition of c-KIT and OX40L, or gene ablation, could be further tested for the enhancement of the anti-tumor activity of NK cells in response to rituximab. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Recurrent Hypoglycemia in a 67-Year-Old Woman with CD5- Positive Diffuse Large B-Cell Lymphoma.
- Author
-
Zhang, Jing, Qiu, Jieyuzhen, Wu, Lipan, Shen, Lin, Gu, Qin, and Tan, Wen
- Subjects
- *
WOMEN , *FATIGUE (Physiology) , *COMPUTED tomography , *IMMUNOTHERAPY , *HYPERHIDROSIS , *POSITRON emission tomography , *BLOOD sugar , *CANCER chemotherapy , *DISEASE relapse , *HYPOGLYCEMIA , *B cell lymphoma , *LYMPHATIC diseases , *DISEASE complications - Abstract
Hypoglycemia is a rare complication of diffuse large B-cell lymphoma. We are presenting a case of 67-year-old woman presented to her primary care physician with fatigue and hyperhidrosis. Laboratory evaluation revealed a glucose level of 1.9 mmol/L. Computed tomographic scan of the abdomen and subsequent positron emission tomographic scan revealed extensive lymphadenopathy. The patient was then diagnosed with CD5-positive -diffuse large B-cell lymphoma and developed recurrent hypoglycemia despite continuous infusion of glucose. Following immunochemotherapy, hypoglycemia was resolved. Several explanations have been postulated but the exact pathophysiology is not well understood. Further investigation is warranted to more clearly define the pathophysiology of persistent hypoglycemia in patients with diffuse large B-cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. CAR T-cells in very elderly (≥80 years) lymphoma patients: a DESCAR-T analysis.
- Author
-
Menez, Simon, Bourbon, Estelle, Gounot, Romain, Tudesq, Jean-Jacques, Moya, Niels, Houot, Roch, and Bachy, Emmanuel
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *B cell lymphoma , *MANTLE cell lymphoma , *CYTOKINE release syndrome , *OLDER patients - Abstract
This document is a letter to the editor discussing the use of CAR T-cell therapy in elderly lymphoma patients aged 80 years and older. The authors report on the outcomes of 12 patients who received CAR T-cell therapy and found that it was feasible and provided some clinical benefit, although efficacy outcomes were slightly lower compared to previous studies. Adverse events were reported, but no severe events occurred. The study suggests that CAR T-cell therapy may be beneficial for selected elderly patients with lymphoma, but more research is needed to confirm these results. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
34. A comprehensive prognostic and immune infiltration analysis of UBA1 in pan‐cancer: A computational analysis and in vitro experiments.
- Author
-
Chen, Can, Li, Yiwei, Chen, Zhenzhen, Shi, Pengfei, Li, Yun, and Qian, Shenxian
- Subjects
B cell lymphoma ,ACUTE myeloid leukemia ,TUMOR classification ,CELL physiology ,CELL cycle - Abstract
Ubiquitin like modifier activating enzyme 1 (UBA1) plays an important role in immune regulation and cellular function. However, the functional mechanism and role of UBA1 in pan‐cancer have not been fully elucidated and its value in haematological tumours (diffuse large B cell lymphoma (DLBC/DLBCL) and acute myeloid leukaemia (AML/LAML)) has not been explored. We conducted a comprehensive analysis of the functional mechanism and role of UBA1 in pan‐cancer using multiple databases, including differential expression analysis, clinical pathological staging analysis, prognosis analysis and immune analysis. Then, we confirmed the function of UBA1 in haematological tumours through cell experiments. The results showed that the expression of UBA1 was significantly increased in most cancers and the differential expression of UBA1 was mainly concentrated in digestive tumours, haematological tumours and brain tumours. Moreover, the high expression of UBA1 had poor prognosis in most tumours, which may be related to its involvement in various cancer‐related pathways such as cell cycle, as well as its methylation level, protein phosphorylation level, immune cell infiltration and immune therapy response. Cell experiments have confirmed that UBA1 can significantly regulate the cycle progression and apoptosis of DLBCL cells and AML cells. Therefore, UBA1 may be a potential therapeutic target for haematological tumours. In summary, our study not only comprehensively analysed the functional mechanisms and clinical value of UBA1 in pan‐cancer, but also validated for the first time the regulatory role of UBA1 in haematological tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management.
- Author
-
Khurana, Arushi, Rosenthal, Allison C., Mohty, Razan, Gaddam, Mamatha, Bansal, Radhika, Hathcock, Matthew A., Nedved, Adrienne N., Durani, Urshila, Iqbal, Madiha, Wang, Yucai, Paludo, Jonas, Villasboas, J. C., Dingli, David, Kourelis, Taxiarchis, Leung, Nelson, Alkhateeb, Hassan, Ruff, Michael W., Gallo de Moraes, Alice, Vergidis, Paschalis, and Herrmann, Joerg
- Subjects
DIFFUSE large B-cell lymphomas ,MANTLE cell lymphoma ,CYTOKINE release syndrome ,CHILD patients ,B cell lymphoma ,DIVERTICULITIS ,INTESTINAL perforation - Abstract
This letter published in the Blood Cancer Journal discusses the clinical presentation, outcomes, and management of chimeric antigen receptor T-cell (CAR-T) therapy-associated hemophagocytic lymphohistiocytosis (HLH) syndrome. The study found that 3% of patients receiving CAR-T therapy developed CAR-T-associated HLH. The document provides detailed information on the clinical presentation, treatment strategies, and outcomes in adult patients with CAR-T-associated HLH. It includes a table with information on different treatment options, toxicities, and laboratory markers. The article emphasizes the importance of early recognition and intervention to prevent fatal outcomes. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
36. Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.
- Author
-
Wang, Lixin, Fang, Chuling, Kang, Qingzheng, Huang, Wenfa, Chen, Ziren, Zhao, Weiqiang, Wang, Lei, Wang, Yiran, Tan, Kun, Guo, Xiao, Xu, Yuanyuan, Wang, Shuhong, Wang, Lijun, Qiao, Jingqiao, Tang, Zhixiong, Yu, Chuan, Xu, Yang, Li, Yisheng, and Yu, Li
- Subjects
B cell lymphoma ,HEMATOLOGIC malignancies ,CHIMERIC antigen receptors ,HOCKEY ,NON-Hodgkin's lymphoma - Abstract
Non-Hodgkin lymphoma (NHL) is a common malignancy in the hematologic system, and traditional therapy has limited efficacy for people with recurrent/refractory NHL (R/R NHL), especially for patients with diffuse large B cell lymphoma (DLBCL). Chimeric antigen receptor (CAR) T-cell therapy is a novel and effective immunotherapy strategy for R/R hematopoietic malignancies, but relapses can occur due to the loss of CAR-T cells in vivo or the loss of antigen. One strategy to avoid antigen loss after CAR-T cell therapy is to target one more antigen simultaneously. Tandem CAR targeting CD19 and CD22 has demonstrated the reliability of tandem CAR-T cell therapy for R/R B-ALL. This study explores the therapeutic potential of tandem CD19/20 CAR-T in the treatment of R/R B cell NHL. The efficacy and safety of autologous CD19/20 CAR-T cells in eleven R/R B cell NHL adult patients were evaluated in an open-label, single-arm trial. Most patients achieved complete response, exhibiting the efficacy and safety of tandem CD19/20 CAR-T cells. The TCR repertoire diversity of CAR-T cells decreased after infusion. The expanded TCR clones in vivo were mainly derived from TCR clones that had increased expression of genes associated with immune-related signaling pathways from the infusion product (IP). The kinetics of CAR-T cells in vivo were linked to an increase in the expression of genes related to immune response and cytolysis/cytotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. PDX Models in Theranostic Applications: Generation and Screening for B Cell Lymphoma of Human Origin.
- Author
-
Shmuel, Shayla, Monette, Sébastien, Ibrahim, Dina, and Pereira, Patrícia M.R.
- Subjects
- *
B cell lymphoma , *HUMAN origins , *B cells , *EPSTEIN-Barr virus , *RESEARCH personnel - Abstract
This MIB guide briefly summarizes the generation of patient-derived xenografts (PDXs) and highlights the importance of validating PDX models for the presence of B cell lymphoma of human origin before their use in radiotheranostic applications. The use of this protocol will allow researchers to learn different methods for screening PDX models for Epstein-Barr virus (EBV)-infected B cell lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Double-Expressor Lymphoma in a Young Child—A Case Report and Review of Literature.
- Author
-
Shaju, Anjali, Sneha, Latha M., Pandian, Nidarshana, Chandra, Suresh, Nisar, Sonam Poonam, Subramanian, Krishnakumar, and Nagarajan, Priyathersini
- Subjects
- *
LITERATURE reviews , *B cell lymphoma , *NON-Hodgkin's lymphoma , *LYMPHOMAS , *FLUORESCENCE in situ hybridization , *DIFFUSE large B-cell lymphomas - Abstract
Double hit lymphoma (DHL) and double-expressor lymphoma (DEL) are now considered as aggressive types of diffuse large B cell lymphoma. DHL is characterized by a dual rearrangement of MYC and B cell lymphoma 2 (BCL-2) and/or B cell lymphoma 6 (BCL-6) and DEL by overexpression of MYC and BCL-2. Both DHL and DEL have aggressive presentation and are more common in elderly population. We present a case of 1 ½ years old boy who presented with bilateral proptosis, and diagnosed as non-Hodgkin lymphoma with central nervous system involvement. Immunohistochemistry revealed high expression of MYC and BCL-2. Fluorescence in situ hybridization studies done to rule out DHL showed no translocation of C-MYC, Bcl-2, and Bcl-6 and hence were confirmed as double-expressor high-grade B cell lymphoma. Dual expression of C- MYC, Bcl-2, or Bcl-6 always needs further evaluation to rule out the more aggressive DHL subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Successful Management of Terminal Delirium With Transdermal Blonanserin Patch in a Terminally Ill Cancer Patient.
- Author
-
Nishiofuku, Hideyuki, Mori, Masanori, Yokomichi, Naosuke, Sakuma, Yumi, Sugiyama, Koichi, Takashina, Yoshiaki, Miyagi, Akemi, Ishizuka, Masato, Imai, Kengo, and Morita, Tatsuya
- Subjects
- *
THERAPEUTIC use of transdermal medication , *DIAGNOSIS of delirium , *ANTIPSYCHOTIC agents , *CANCER patients , *AGITATION (Psychology) , *MIDAZOLAM , *CANCER pain , *CANCER chemotherapy , *DELIRIUM , *TERMINALLY ill , *TERMINAL care , *B cell lymphoma - Abstract
Delirium is a distressing condition in terminally ill cancer patients, often treated with antipsychotics. Administering them orally, subcutaneously, or intravenously can be challenging in severely agitated patients. Transdermal antipsychotic patches offer an alternative, but their use for terminal delirium remains underexplored. We present the case of a 73-year-old man with advanced diffuse large B cell lymphoma who developed severe mixed delirium during third-line chemotherapy. Nonpharmacological interventions and oral risperidone plus intravenous haloperidol failed to improve his condition. Subsequently, a transdermal blonanserin patch was applied, resulting in the resolution of hallucinations on day 1 and agitation on day 3, allowing improved communication. The patch was easily applied daily without notable adverse events. However, he deteriorated a week later with an estimated survival of days, ultimately requiring continuous midazolam for refractory agitation. This case underscores the potential of transdermal blonanserin patches for delirium in terminally ill cancer patients, emphasizing the need for future prospective studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation.
- Author
-
Viscovo, Marcello, Clemmensen, Mia de Laurent, Fosso, Federica, Maiolo, Elena, Autore, Francesco, Laurenti, Luca, Hohaus, Stefan, and Chiusolo, Patrizia
- Subjects
- *
CHRONIC lymphocytic leukemia , *MULTIPLE myeloma , *RESEARCH funding , *POLYMERASE chain reaction , *DESCRIPTIVE statistics , *ROUTINE diagnostic tests , *GENETIC mutation , *LYMPHOPROLIFERATIVE disorders , *CONFIDENCE intervals , *MONOCLONAL gammopathies , *B cell lymphoma , *SENSITIVITY & specificity (Statistics) - Abstract
Introduction: Agarose gel‐based conventional and real‐time allele‐specific polymerase chain reaction (AS‐PCR) assays are currently used for sensitive detection and quantification of MYD88 L265P mutation. Visual inspection of an agarose gel can often be ambiguous. We propose a new allele‐specific quantification PCR (AS‐qPCR) assay, PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay, that uses Intercalating Nucleic Acid (INA®) technology for increased affinity and specificity. Methods: This study compares PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay with conventional AS‐PCR. We included a total of 102 peripheral and bone marrow blood samples from 94 patients with a lymphoproliferative disorder. Droplet digital PCR (ddPCR) was used as a third method in case of discrepancy. Results: A positive percent agreement of 100% (95% CI 0.92–1.0) and a negative percent agreement of 98% (95% CI 0.90–1.0) were found between the conventional AS‐PCR and the AS‐qPCR methods. Including the ddPCR results to validate the discrepant cases, the sensitivity and specificity of PlentiPlex™ MYD88 Waldenström lymphoma qPCR Assay were 1.0 (95% CI 0.97–1.0) and 1.0 (95% CI 0.96–1.0), respectively. Conclusion: Our data demonstrate that PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay is a fast, highly sensitive, and specific method for the detection of MYD88 L265P compared with conventional AS‐PCR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia.
- Author
-
Petgrave, Yonique, Selukar, Subodh, Epperly, Rebecca, Naik, Swati, Santos, Noel DeLos, Triplett, Brandon M., Gottschalk, Stephen, Bissler, John, and Talleur, Aimee C.
- Subjects
- *
IMMUNIZATION , *RESEARCH funding , *THERAPEUTICS , *RENAL replacement therapy , *ACUTE kidney failure , *RETROSPECTIVE studies , *SEVERITY of illness index , *LYMPHOBLASTIC leukemia , *B cell lymphoma , *CELL receptors , *DISEASE incidence , *ADOLESCENCE , *CHILDREN , *ADULTS - Abstract
Background: CD19-specific chimeric antigen receptor (CAR) T-cell therapy has shown promising disease responses in patients with high-risk B-cell malignancies. However, its use may be related to complications such as immune-mediated complications, infections, and end-organ dysfunction. The incidence of post-CAR T-cell therapy acute kidney injury (AKI) in the children, adolescent, and young adult (CAYA) patient population is largely unreported. Methods: The objectives of this study were to determine the incidence of AKI in CAYA patients with high-risk B-cell malignancies treated with CD19-CAR T-cell therapy, evaluate potential risk factors for developing AKI, and determine patterns of kidney function recovery. We conducted a retrospective analysis of 34 CAYA patients treated with CD19-CAR T-cell at a single institution. Results: There was a cumulative incidence of any grade AKI by day 30 post-infusion of 20% (n = 7), with four cases being severe AKI (stages 2–3) and one patient requiring kidney replacement therapy. All episodes of AKI developed within the first 14 days after receiving CAR T-cell therapy and 50% of patients with AKI recovered kidney function to baseline within 30 days post-infusion. No evaluated pre-treatment risk factors were associated with the development of subsequent AKI; there was an association between AKI and cytokine release syndrome and neurotoxicity. We conclude that the risk of developing AKI following CD19-CAR T-cell therapy is highest early post-infusion, with most cases of AKI being severe. Conclusions: Frequent monitoring to facilitate early recognition and subsequent management of kidney complications after CD19-CAR T-cell therapy may reduce the severity of AKI in the CAYA patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL).
- Author
-
McKeown, James P., Byrne, Andrew J., Bright, Sandra A., Charleton, Clara E., Kandwal, Shubhangi, Čmelo, Ivan, Twamley, Brendan, McElligott, Anthony M., Fayne, Darren, O'Boyle, Niamh M., Williams, D. Clive, and Meegan, Mary J.
- Subjects
- *
MONONUCLEAR leukocytes , *CHRONIC lymphocytic leukemia , *B cell lymphoma , *MALEIC anhydride , *BONE marrow - Abstract
Chronic lymphocytic leukemia (CLL) is a malignancy of mature B cells, and it is the most frequent form of leukemia diagnosed in Western countries. It is characterized by the proliferation and accumulation of neoplastic B lymphocytes in the blood, lymph nodes, bone marrow and spleen. We report the synthesis and antiproliferative effects of a series of novel ethanoanthracene compounds in CLL cell lines. Structural modifications were achieved via the Diels–Alder reaction of 9-(2-nitrovinyl)anthracene and 3-(anthracen-9-yl)-1-arylprop-2-en-1-ones (anthracene chalcones) with dienophiles, including maleic anhydride and N-substituted maleimides, to afford a series of 9-(E)-(2-nitrovinyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-diones, 9-(E)-3-oxo-3-phenylprop-1-en-1-yl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-diones and related compounds. Single-crystal X-ray analysis confirmed the structures of the novel ethanoanthracenes 23f, 23h, 24a, 24g, 25f and 27. The products were evaluated in HG-3 and PGA-1 CLL cell lines (representative of poor and good patient prognosis, respectively). The most potent compounds were identified as 20a, 20f, 23a and 25n with IC50 values in the ranges of 0.17–2.69 µM (HG-3) and 0.35–1.97 µM (PGA-1). The pro-apoptotic effects of the potent compounds 20a, 20f, 23a and 25n were demonstrated in CLL cell lines HG-3 (82–95%) and PGA-1 (87–97%) at 10 µM, with low toxicity (12–16%) observed in healthy-donor peripheral blood mononuclear cells (PBMCs) at concentrations representative of the compounds IC50 values for both the HG-3 and PGA-1 CLL cell lines. The antiproliferative effect of the selected compounds, 20a, 20f, 23a and 25n, was mediated through ROS flux with a marked increase in cell viability upon pretreatment with the antioxidant NAC. 25n also demonstrated sub-micromolar activity in the NCI 60 cancer cell line panel, with a mean GI50 value of 0.245 µM. This ethanoanthracene series of compounds offers potential for the further development of lead structures as novel chemotherapeutics to target CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Unusual Presentation of Non-Hodgkin Lymphoma of Two Cases: Case Report.
- Author
-
S, Haritha, Sudarsan, Shyam Sudhakar, Anbarasan, Subagar, and Sankar, Sakthimurugan
- Subjects
- *
B cell lymphoma , *NON-Hodgkin's lymphoma , *HOCKEY , *TONSILS , *LYMPHOMAS - Abstract
Lymphomas are a diverse group of neoplastic disorders arising primarily in lymph nodes. They have been majorly classified into Hodgkin and Non-Hodgkin lymphomas(NHL). NHL can be of B, T and Null cell categories having further subtypes based on their histological characteristics. Lymphomas can be nodal and extra nodal. The head and neck area are the second most common site of extra nodal lymphoma, with tonsils being the most common site of involvement; other sites include the nasopharynx and tongue base. B- Cell type being the most common type. Predominantly occurs in elderly. Presentations depends on the site involved. Various modalities like surgical treatment, chemotherapy (or) radiotherapy is available. Each stage has varied survival rates and prognosis and responses to the treat depending on the patient factors. In this paper, we report two cases of patients with non-Hodgkin lymphoma of tonsil, where the preoperative clinical diagnosis and radiological diagnosis was inconclusive and final diagnosis was established based on histopathological examination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain.
- Author
-
Córdoba, Raúl, López-Corral, Lucía, Presa, María, Martín-Escudero, Victoria, Vadgama, Sachin, Casado, Miguel Ángel, and Pardo, Carlos
- Subjects
- *
HEALTH services accessibility , *QUALITY-adjusted life years , *RESEARCH funding , *IMMUNOTHERAPY , *CELLULAR therapy , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *MATHEMATICAL models , *THEORY , *QUALITY assurance , *DATA analysis software , *B cell lymphoma , *CELL receptors - Abstract
Simple Summary: Axicabtagene ciloleucel (axi-cel) has been shown to improve the health outcomes of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, the actual number of patients treated in Spain is lower than the epidemiology estimations. The aim of our study was to assess the value of axi-cel versus chemotherapy in patients with R/R DLBCL after ≥2 lines of therapy based on the number of patients treated. Considering that the entire cohort was eligible for treatment with axi-cel (n = 490) compared to the currently treated population (n = 187), the use of axi-cel rather than chemotherapy in all eligible patients could lead to 2173 life years gained and 1706 quality-adjusted life years. Furthermore, if all eligible patients were treated with CAR T-cell therapy, an additional 85 patients would be alive, and 78 patients would be alive without disease progression at 5 years. In this study, the health impacts of improving access to treatment with axicabtagene ciloleucel (axi-cel) was assessed in patients with relapsed/refractory diffuse large B-cell lymphoma after ≥2 lines of therapy in Spain. A partitioned survival mixture cure model was used to estimate the lifetime accumulated life years gained (LYG) and quality-adjusted life years (QALYs) per patient treated with axi-cel versus chemotherapy. Efficacy data were extracted from the ZUMA-1 trial for axi-cel and from the SCHOLAR-1 study for chemotherapy. In the base case, the incremental outcomes of axi-cel versus chemotherapy were evaluated in a cohort of 187 patients treated with CAR T-cell therapies, as reported by the "Spanish National Health System Plan for Advanced Therapies", and in the alternative scenario in the full eligible population based on epidemiological estimates (n = 490). Taking those currently treated with axi-cel, compared with chemotherapy, axi-cel provided an additional 1341 LYGs and 1053 QALYs. However, when all eligible patients (n = 490) were treated, axi-cel provided an additional 3515 LYs and 2759 QALYs. Therefore, if all eligible patients were treated with axi-cel rather than those currently treated as per the registry (n = 187), there would have been an additional 303 patients treated, resulting in an additional 2173 LYGs and 1706 QALYs in total. The lack of access in Spain has led to a loss of a substantial number of LYGs and QALYs, and efforts should be made to improve access for all eligible patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis.
- Author
-
Maerevoet, Marie, Casasnovas, Olivier, Cartron, Guillaume, Morschhauser, Franck, Thieblemont, Catherine, Bouabdallah, Kamal, Feugier, Pierre, Szablewski, Vanessa, Becker, Stephanie, and Tilly, Herve
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *PLATINUM compounds , *CANCER relapse , *RESEARCH funding , *NON-Hodgkin's lymphoma , *DISEASE duration , *ANTINEOPLASTIC agents , *CLINICAL trials , *RITUXIMAB , *ORAL drug administration , *CANCER patients , *DESCRIPTIVE statistics , *CANCER chemotherapy , *GEMCITABINE , *DRUG efficacy , *B cell lymphoma , *DEXAMETHASONE - Abstract
Simple Summary: The chemotherapy combination rituximab, gemcitabine, and dexamethasone (R-GDP), followed by high-dose chemotherapy and autologous stem cell transplantation, is one of the standards of care for relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL). Complete metabolic response before transplantation is the most important prognosis factor for a long duration of remission. Selinexor is an oral, selective inhibitor of the nuclear export compound (XPO1). For heavily pretreated patients with DLBCL, the single drug selinexor has previously shown an overall response rate of 29%. In this study, we evaluated selinexor in combination with RGDP for patients with R/R B-cell lymphoma. The results from our phase I clinical study indicate that weekly selinexor plus RGDP has a generally tolerable safety profile and durable efficacy in R/R B-NHL. Purpose: Selinexor is an oral selective inhibitor of exportine-1 (XPO1) with efficacy as a single agent in heavily pretreated diffuse large B-cell lymphoma (DLBCL). We conducted a study investigating the combination of selinexor with rituximab and platinum-based chemotherapy in B-cell lymphoma. Patients and methods: We conducted a phase 1b, dose-escalation, and expansion trial, which enrolled patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Patients received oral selinexor according to a 3 + 3 design in combination with rituximab and dexamethasone, high-dose cytarabine, oxaliplatine (DHAOX) or gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy. Results: A total of 39 patients were enrolled, 27 during the escalation phase and 12 during the expansion phase. Most patients had diffuse large B-cell lymphoma (DLBCL; 77%). Group R-DHAOX was prematurely closed to inclusion due to a recommendation from the French drug agency, independent of this trial. A recommended phase 2 dose (RP2D) of selinexor in association with R-GPD was established at 40 mg on days 1, 8, and 15 of each 21-day cycle. In a population of 18 patients treated at this dose of selinexor, the most frequent grade 3–4 adverse events were hematological. With this regimen, seven obtained a complete metabolic response and five a partial response. The median PFS was 5.8 months. Conclusions: Among the patients with R/R B-cell lymphoma, selinexor at a weekly dose of 40 mg with R-GDP is feasible for outpatients, with a generally acceptable safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Assessment of Ki-67 Proliferative Index in Cytological Samples of Nodal B-Cell Lymphomas.
- Author
-
Založnik, Mojca, Miceska, Simona, Buček, Simon, Nolde, Nataša, Gjidera, Mojca, Klopčič, Ulrika, Čekić, Zorica, Pohar Marinšek, Živa, Gašljević, Gorana, and Kloboves Prevodnik, Veronika
- Subjects
- *
NEEDLE biopsy , *B cell lymphoma , *CELL suspensions , *KI-67 antigen , *FLOW cytometry - Abstract
Background: The Ki-67 proliferative index (PI) is part of the diagnosis of nodal B-cell lymphoma (nBCL), but its determination in cytological samples is not standardized. We aimed to establish an approach for the accurate determination of the Ki-67 PI in cytological slides to differentiate between indolent and aggressive nBCLs. Methods: Patients diagnosed with nBCL by fine-needle aspiration biopsy and subsequent excision biopsy were included. Cell suspensions were prepared from biopsy samples for CD3/Ki-67 double immunocytochemical staining and flow-cytometric verification of lymphoma B-cell counts. The Ki-67 PI was assessed by manual counting and eyeballing in cytology and eyeballing in histology. The cut-off values for the differentiation between aggressive and indolent lymphomas were determined for each method. Results: A strong correlation between manual and flow-cytometric counting of lymphoma B cells was confirmed (interclass correlation coefficient (IC coef.) = 0.78). The correlation of the Ki-67 PI determined in cytological and histological slides was also strong (IC coef. > 0.80). Histologically, 55 cases were classified as indolent and 31 as aggressive nBCLs. KI-67 PI cut-off values of 28.5%, 27.5%, and 35.5% were established for manual counting and eyeballing in cytology and eyeballing in histology, respectively, with high sensitivity and specificity. Conclusions: The Ki-67 PI, assessed by manual counting and eyeballing in cytological samples, accurately differentiates between indolent and aggressive nBCLs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Imbalance of B-Cell Subpopulations in the Microenvironment of Sarcoidosis or Lung Cancer.
- Author
-
Raniszewska, Agata, Kwiecień, Iwona, Rutkowska, Elżbieta, Bednarek, Joanna, Sokołowski, Rafał, Miklusz, Piotr, Rzepecki, Piotr, and Jahnz-Różyk, Karina
- Subjects
- *
B cell lymphoma , *IMMUNOMODULATORS , *IMMUNOLOGIC memory , *LYMPH node cancer , *T cells , *B cells - Abstract
Although the role of T lymphocytes in sarcoidosis (SA) and lung cancer (LC) is quite well reported, the occurrence of B cells in disease microenvironments may suggest their potential role as natural modifiers of the immune response. The aim of this study was to investigate the B-cell profile and lymphocyte-related hematological parameters between patients with SA, LC and healthy controls (HCs). The cells were assessed by flow cytometry and a hematological analyzer in peripheral blood (PB) and material from lymph nodes (LNs) obtained by the EBUS/TBNA method. We showed that in SA patients, there were higher percentages of naïve B and CD21low B cells and a lower percentage of class-switched memory B cells than LC patients in LNs. We observed a higher median proportion of non-switched memory and transitional B cells in the PB of SA patients than in LC patients. We noticed the lowest median proportion of class-switched memory B cells in the PB from SA patients. LC patients had a higher percentage of RE-LYMP and AS-LYMP than SA patients. Our study presented a different profile of B-cell subpopulations in SA and LC patients, distinguishing dominant subpopulations, and showed the relocation from distant compartments of the circulation to the disease microenvironment, thus emphasizing their role. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. The 53rd Annual Meeting of The Japanese Society of Neuroradiology 9 – 10 February 2024, Saitama, Japan.
- Subjects
- *
NEUROMYELITIS optica , *MEETINGS , *GLIOMAS , *CONFERENCES & conventions , *NEURORADIOLOGY , *CEREBRAL infarction , *BRAIN tumors , *B cell lymphoma - Published
- 2024
- Full Text
- View/download PDF
49. Serial regression of primary gastric diffuse large B cell lymphoma after Helicobacter pylori eradication therapy: A case report.
- Author
-
Lyu, Ting‐Wei, Yu, Shan‐Chi, and Lin, Chien‐Chin
- Subjects
- *
B cell lymphoma , *MUCOSA-associated lymphoid tissue lymphoma , *LYMPHOID tissue , *HELICOBACTER pylori , *LYMPHOMAS - Abstract
Key Clinical Message: Primary gastric diffuse large B‐cell lymphoma (DLBCL), a rare malignancy linked to Helicobacter pylori (HP) infection, in this case regressed to low‐grade lymphoma and then achieved complete remission after HP eradication (HPE), highlighting this unique interim change and the potential of HPE as an effective treatment for early‐stage cases. Primary gastric diffuse large B‐cell lymphoma (DLBCL) is a rare malignancy. Like gastric mucosa‐associated lymphoid tissue (MALT) lymphoma, HP infection is implicated in lymphomagenesis and has thus emerged as a therapeutic target. Studies have demonstrated the sustained efficacy of HP eradication alone for limited‐stage primary gastric DLBCL. This report presents the case of a 53‐year‐old woman with stage IE gastric DLBCL who received triple therapy for HP eradication and experienced an interim histological transformation to MALT lymphoma, ultimately achieving complete pathologic remission. HP eradication therapy may represent a viable treatment option for patients with early‐stage primary gastric DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Human CD4+iNKT cell adoptive immunotherapy induces anti‐tumour responses against CD1d‐negative EBV‐driven B lymphoma.
- Author
-
Baiu, Dana C., Sharma, Akshat, Schehr, Jennifer L., Basu, Jayati, Smith, Kelsey A., Ohashi, Makoto, Johannsen, Eric C., Kenney, Shannon C., and Gumperz, Jenny E.
- Subjects
- *
CD14 antigen , *B cell lymphoma , *IMMUNOTHERAPY , *T cells , *CELL imaging , *LYMPHOMAS - Abstract
Invariant natural killer T (iNKT) cells are a conserved population of innate T lymphocytes that are uniquely suitable as off‐the‐shelf cellular immunotherapies due to their lack of alloreactivity. Two major subpopulations of human iNKT cells have been delineated, a CD4− subset that has a TH1/cytolytic profile, and a CD4+ subset that appears polyfunctional and can produce both regulatory and immunostimulatory cytokines. Whether these two subsets differ in anti‐tumour effects is not known. Using live cell imaging, we found that CD4− iNKT cells limited growth of CD1d+ Epstein–Barr virus (EBV)‐infected B‐lymphoblastoid spheroids in vitro, whereas CD4+ iNKT cells showed little or no direct anti‐tumour activity. However, the effects of the two subsets were reversed when we tested them as adoptive immunotherapies in vivo using a xenograft model of EBV‐driven human B cell lymphoma. We found that EBV‐infected B cells down‐regulated CD1d in vivo, and administering CD4− iNKT cells had no discernable impact on tumour mass. In contrast, xenotransplanted mice bearing lymphomas showed rapid reduction in tumour mass after administering CD4+ iNKT cells. Immunotherapeutic CD4+ iNKT cells trafficked to both spleen and tumour and were associated with subsequently enhanced responses of xenotransplanted human T cells against EBV. CD4+ iNKT cells also had adjuvant‐like effects on monocyte‐derived DCs and promoted antigen‐dependent responses of human T cells in vitro. These results show that allogeneic CD4+ iNKT cellular immunotherapy leads to marked anti‐tumour activity through indirect pathways that do not require tumour cell CD1d expression and that are associated with enhanced activity of antigen‐specific T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.